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Glucagon, secreted by pancreatic islet a cells, is
the principal hyperglycemic hormone. In diabetes,
glucagon secretion is not suppressed at high
glucose, exacerbating the consequences of insuffi-
cient insulin secretion, and is inadequate at low
glucose, potentially leading to fatal hypoglycemia.
The causal mechanisms remain unknown. Here we
show that a cell KATP-channel activity is very low
under hypoglycemic conditions and that hyperglyce-
mia, via elevated intracellular ATP/ADP, leads to
complete inhibition. This produces membrane depo-
larization and voltage-dependent inactivation of the
Na+ channels involved in action potential firing that,
via reduced action potential height and Ca2+ entry,
suppresses glucagon secretion. Maneuvers that
increase KATP channel activity, such as metabolic
inhibition, mimic the glucagon secretory defects
associated with diabetes. Low concentrations of
the KATP channel blocker tolbutamide partially
restore glucose-regulated glucagon secretion in
islets from type 2 diabetic organ donors. These
data suggest that impaired metabolic control of the
KATP channels underlies the defective glucose regu-
lation of glucagon secretion in type 2 diabetes.
INTRODUCTION
Glucagon and insulin are the body’s principal plasma glucose-
regulating hormones. They are secreted from the a and b cells
of the pancreatic islets, respectively. Physiologically, glucagon
is released in response to a fall in plasma glucose levels, an in-
crease in amino acids, and b-adrenergic stimulation (Gromada
etal., 2007).Diabetes isabihormonaldisorder involvingboth inad-Cell Mequate insulin secretion and defective glucagon secretion. The
glucagon secretory defects include oversecretion at high glucose
(when it is not needed) and inadequate release at low glucose
(when it is needed) (Cryer, 2002; Unger and Cherrington, 2012).
Whereas the cellular regulation of insulin secretion is fairly well
understood (Remedi andNichols, 2009; Seino et al., 2011), much
less is known about the control of glucagon secretion (Gaisano
et al., 2012). Hypotheses for the regulation of glucagon secretion
include paracrine effects, mediated by factors released from
neighboring insulin-secreting b cells or somatostatin-secreting
d cells, or innervation (Gromada et al., 2007). However, in both
human and rodent islets, glucagon secretion is strongly inhibited
by glucose concentrations that have little stimulatory effect on
insulin secretion (Walker et al., 2011), and glucose remains
capable of suppressing secretion following pharmacological or
immunological inhibition of somatostatin signaling (de Heer
et al., 2008; Vieira et al., 2007). Moreover, glucagon secretion
responds normally to hypoglycemia after denervation of the
pancreas (Sherck et al., 2001). These considerations suggest
that a cells, in addition to being under paracrine control, possess
an intrinsic glucose-sensing mechanism. This remains poorly
defined, but studies on KATP-channel knockout mice indicate
that KATP-channels are somehow involved (Cheng-Xue et al.,
2013; Gromada et al., 2004; Mun˜oz et al., 2005; Shiota et al.,
2005) and the inhibitory effect of high glucose can be reversed
by low concentrations of the KATP-channel activator diazoxide
(Go¨pel et al., 2000b; MacDonald et al., 2007). In pancreatic b
cells, closure of these channels by metabolically generated
ATP leads to membrane depolarization, electrical activity, and
insulin secretion. It is not immediately evident, however, how
regulation of the same channels by glucose in a cells could sup-
press glucagon secretion. To date, most studies have failed to
detect an effect of glucose on a cell KATP-channel activity
(Barg et al., 2000; Bokvist et al., 1999; Quoix et al., 2009;
Ramracheya et al., 2010), but one study reported a small
glucose-induced decrease in KATP channel activity that, para-
doxically, was associated with stimulation rather than inhibition
of glucagon secretion (Olsen et al., 2005). Notably, all theseetabolism 18, 871–882, December 3, 2013 ª2013 The Authors 871
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Figure 1. Regulation of Glucagon Secretion
by Glucose and Tolbutamide
(A) Glucagon secretion from mouse islets at 1 mM
and 6 mM glucose in the absence and presence of
10 mM mannoheptulose (MH, n = 6). *p < 0.05
versus 1 mM glucose; yp < 0.05 versus 6 mM
glucose without mannoheptulose.
(B) (Left) Representative traces of the increase
in [ATP/ADP]cyt measured as D(F/F0) recorded
from individual a cells within the islet, in res-
ponse to 6 mM glucose and 2 mM FCCP. The
gray line represents parallel measurements of
tdRFP fluorescence in the a cell. The data
are representative of 44 a cells in 9 intact
islets from 3 different animals. (Right) Confocal
images of Perceval (green), tdRFP (red), and the
combination of the two (yellow). Scale bar,
200 mm.
(C) Glucagon secretion from muse islets in the
absence or presence of CYN154806 (which
blocks SSTR2, the main somatostatin receptor
subtype in a cells; Yue et al., 2012) at 1 mM or
6 mM glucose (left) or with and without tolbuta-
mide (0.1 mM, right; n = 6–7). *p < 0.05 or **p <
0.01 versus 1 mM glucose; yyp < 0.01 versus 6 mM
glucose without CYN154806.
(D) Insulin and glucagon secretion were
measured using the perfused pancreas pre-
paration. Data are normalized to the maximal insulin or glucagon secretion in each mouse (n = 5–7). For clarity, significances are not indicated, but effects
of glucose and tolbutamide on insulin and glucagon secretion were statistically significant (*p < 0.05 or better).
Error bars indicate SEM.
Cell Metabolism
KATP Channels and Glucagon Secretionstudies of KATP-channel activity used isolated a cells in tissue
culture. Tissue culture and/or deprivation of the normal intercel-
lular milieu following islet dissociation may affect a cell function
via altered gene transcription, protein expression, or loss of
normal paracrine signaling. To avoid such potential confounding
effects, the experiments now reported were (whenever techni-
cally feasible) performed on a cells in freshly isolated intact islets.
Here we show that glucose-induced inhibition of KATP-chan-
nels in a cells results in inhibition of glucagon secretion, that
the glucagon secretory defects associated with diabetes can
be mimicked by experimental conditions leading to a tiny in-
crease in KATP-channel activity, and that glucose-regulated
glucagon secretion can be restored in diabetic or metabolically
compromised islets by low concentrations of the KATP-channel
blocker tolbutamide.
RESULTS
Glucose Regulates Glucagon Secretion by an Intrinsic,
Nonparacrine Mechanism
We first established that the inhibitory effect of glucose on
glucagon secretion is secondary to glucose metabolism.
Mannoheptulose, an inhibitor of glucose phosphorylation,
abolished the inhibitory effect of 6 mM glucose on glucagon
secretion, without affecting hormone release at 1 mM glucose
(Figure 1A).
We used the fluorescent probe Perceval to measure the cyto-
solic ATP/ADP ratio ([ATP]/[ADP]cyt) in a cells of intact mouse
islets (Figure 1B). Addition of the mitochondrial uncoupler
FCCP promptly decreased [ATP]/[ADP]cyt.. On average, glucose
increased [ATP]/[ADP]cyt (measured as relative increase in872 Cell Metabolism 18, 871–882, December 3, 2013 ª2013 The AutPerceval fluorescence above basal) by 33% ± 2% (n = 44; p <
0.02, Mann-Whitney U test for independent samples). In these
experiment, a cells were identified by tdRFP fluorescence. We
have considered the possibility that tdRFP might interfere with
the ATP measurements. However, we do not think this is the
case. First, background tdRFP fluorescence was stable and un-
affected by glucose or FCCP (Figure 1B). Second, effects of
glucose in a cells identified by spontaneous oscillations in
[Ca2+]i at 1 mM glucose were very similar to those seen in a cells
identified by tdRFP fluorescence. Thus, we conclude that
glucose increases ATP in a cells. These findings are in agree-
ment with earlier reports of a small (10%–20%) increase in cyto-
plasmic [ATP] (Ishihara et al., 2003; Ravier and Rutter, 2005) and
of total ATP and ADP (Detimary et al., 1998) in response to
glucose in a cells using alternative methods of measurement.
Both somatostatin and insulin have been proposed to mediate
the inhibitory effects of glucose on glucagon secretion in intact
islets (Unger and Cherrington, 2012; Unger and Orci, 2010).
The somatostatin receptor subtype 2 (SSTR2) antagonist
CYN154806 increased glucagon secretion at both 1 and 6 mM
glucose, suggesting a cells are under tonic somatostatin inhibi-
tion. In freshly isolated islets, tolbutamide (unlike what was pre-
viously observed in cultured islets; Cheng-Xue et al., 2013)
remained inhibitory on glucagon secretion when somatostatin
signaling was acutely inhibited using CYN154806 (Figure 1C).
Figure 1D shows the reciprocal increase in insulin secretion
and decrease in glucagon secretion produced when glucose is
lowered from 6mM to 1 mM. Glucagon secretion was maximally
stimulated before any detectable inhibition of insulin secretion.
Tolbutamide produced a transient 10-fold stimulation of insulin
secretion and mimicked the inhibitory effect of glucose onhors
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Figure 2. Effects of Glucose, Tolbutamide, and Diazoxide on
Electrical Activity in a Cells
(A–C) (Left) Electrical activity in mouse a cells (identified by action potential
firing at 1 mM glucose) at 1 mM and 6 mM glucose (A, n = 9), 200 mM tolbu-
tamide (B, n = 5), or 1 or 100 mM diazoxide (C, n = 5). (Right) Averaged action
potentials recorded around the indicated time points, shown on an expanded
timescale (averages of 308 and 181 spikes at 1 and 6 mM glucose in A; 54 and
223 in the absence and presence of tolbutamide in B; and 277, 560, and 190 at
1 mM and 6 mM glucose, and 6mM glucose + 1 mM diazoxide in C). See also
Figures S1 and S2 and Table S1.
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KATP Channels and Glucagon Secretionglucagon secretion, but glucagon secretion remained sup-
pressed even when stimulated insulin release had decayed by
80%. The report that glucagon secretion evoked by insulin-
induced hypoglycemia is not very different in control mice and
in mice lacking insulin receptors in a cells (Kawamori et al.,
2009) provides additional evidence for a dissociation between
insulin and glucagon secretion.
Collectively, these data suggest that glucose inhibits glucagon
secretion by mechanisms that do not require paracrine effects
of insulin or somatostatin (or signals coreleased with these
hormones). However, paracrine mechanisms may become
functionally more significant under physiological situations
associated with strong stimulation of insulin and somatostatin
secretion.
Effects of Glucose and Pharmacological Modulators of
KATP Channel Activity on a Cell Electrical Activity
Unlike insulin-secreting b cells and somatostatin-secreting
d cells (Go¨pel et al., 2000a), pancreatic a cells in intact mouse
islets exposed to 1 mM glucose (i.e., when glucagon secretion
is stimulated) generate spontaneous action potentials (Fig-
ure 2A). The frequency, the peak voltage, and the most negative
membrane potential attained during action potential firing aver-
aged 1.4 ± 0.3 Hz, 2 ± 3mV, and54 ± 2mV (n = 9). Correspond-
ing values in the presence of 6 mM glucose (when glucagon
secretion is maximally suppressed) were 3.0 ± 0.5 Hz (p <
0.02), 7 ± 2 mV (p < 0.002), and 45 ± 2 mV (p < 0.01; n = 9).
Averaged action potentials (see Experimental Procedures) re-Cell Mcorded under the indicated experimental conditions are shown
on the right on an expanded time base.
Tolbutamide mimicked the effect of elevating glucose (Fig-
ure 2B). It depolarized a cells by 11 ± 3 mV (p < 0.02), reduced
action potential peak voltage by 17 ± 6 mV (p < 0.02), and
increased firing frequency to 3.3 ± 0.7 Hz (p < 0.02; n = 5).
The effect of the KATP-channel activator diazoxide on a cells
exposed to 6 mM glucose was concentration dependent (Fig-
ure 2C). At 100 mM, it hyperpolarized a cells to 74 ± 4 mV
(p < 0.01; n = 4) and abolished action potential firing. At 1 mM it
hyperpolarized a cells by 9 ± 2mV (p < 0.01) yet increased action
potential peak voltage by 7 ± 2 mV (p < 0.02, n = 5).
The maximum rate of depolarization (dV/dtd) during the up-
stroke of the action potential averaged 37 ± 6 V/s (n = 11) at
1mMglucose, 15 ± 3 V/s (n = 11; p < 0.001 versus 1mMglucose)
at 6mMglucose (or 0.2mM tolbutamide), and 33 ± V/s (n = 5; p <
0.02 versus 6 mM glucose) in the presence of 6 mM glucose and
1 mM diazoxide. Corresponding values for the maximum rate of
repolarization (dV/dtr) averaged 24 ± 3 V/s, 13 ± 1 V/s (p <
0.01 versus 1 mM glucose), and 31 ± 6 V/s (p < 0.05 versus
6mMglucose).We attribute the slower repolarization in the pres-
ence of glucose or tolbutamide to reduced voltage-dependent
activation of the K+-channels involved in action potential repolar-
ization when spike height is reduced.
In a small number of experiments (4 of 29 cells), elevating
glucose transiently hyperpolarized the a cell and suppressed
action potential firing (Figure S1A available online). This could
be antagonized by CYN154806, suggesting it may result from
somatostatin released by neighboring d cells (Figure S1B).
Some a cells hyperpolarized spontaneously in the continued
presence of 1 mM glucose (Figure S1C). This repolarization
and suppression of electrical activity lasted 5 min, after which
the a cell depolarized and action potential firing resumed. Spon-
taneous membrane potential oscillations were seen in a cells
exposed to 1 mM glucose in 60% of experiments. These prob-
ably account for the [Ca2+]I oscillations with a period of 5 min
seen in isolated islets at low glucose (Figure S1D). The frequency
and amplitude of these oscillations were little affected by 6 mM
glucose, as previously reported (LeMarchand and Piston, 2010).
Effects of Glucose and Tolbutamide on Whole-Cell KATP
Channel Activity
Figures 2A–2C suggest that, at 1 mM glucose, a cells exhibit low
KATP-channel activity and that glucose acts by modulating this
activity. We therefore recorded whole-cell KATP-current under
voltage-clamp conditions in identified a cells (Figures S2C and
S2D) in intact islets (Figure 3A). Data are expressed as changes
in whole-cell conductance (G). At 1 mM glucose, G was 270 ±
50 pS (n = 16). Increasing glucose to 6 mM, or addition of tolbu-
tamide, reducedG by 75 ± 39 pS (p < 0.05; n = 16) and 76 ± 32 pS
(p < 0.01; n = 14), respectively. Tolbutamide was ineffective at
6 mM glucose (data not shown), as expected if glucose had
already closed KATP-channels. The glucose- and tolbutamide-
induced changes in G were small—less than 3% of those seen
in b cells under comparable conditions (Zhang et al., 2008). How-
ever, intracellular application of 0.1 mM ADP (to maximally acti-
vate KATP-channels) increased G from an initial value of 0.30 ±
0.03 nS to 11 ± 2 nS (n = 5; Figures S2A and S2B). Thus, the
KATP-channel is under strong tonic inhibition (>99%) in a cells.etabolism 18, 871–882, December 3, 2013 ª2013 The Authors 873
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Figure 3. Modulation of KATP Channel Activ-
ity by Glucose in Mouse Pancreatic a Cells
(A) (Left) Perforated patch whole-cell currents in
mouse a cells evoked by ±10 mV voltage pulses
(indicated schematically above the current traces)
at 1 mM glucose (black) and 6 mM glucose
(red, +glc.) or 1 mM glucose plus 100 mM tolbu-
tamide (red, +tolb.). Histograms (right) show mean
whole-cell KATP-currents (expressed as mem-
brane conductance) in glucose and tolbutamide,
as indicated. *p < 0.05 versus 1 mM glucose.
(B) Dose-response curve for the effects of
increasing concentrations of diazoxide (1–300 mM)
on the whole-cell KATP-channel activity (expressed
as membrane conductance) in a cells within intact
islets. *p < 0.05 versus no diazoxide for concen-
trations >1 mM (not indicated for clarity). (Inset)
Perforated patch whole-cell currents in mouse a
cells evoked by ±10 mV voltage pulses at 6 mM
glucose (black) and 6 mM glucose + 3 mM diazo-
xide (red, +diaz.).
(C) Relationship between glucagon secretion and
mean whole-cell conductance (G, perforated
patch) in mouse a cells at 6 mM glucose and the
indicated diazoxide concentrations (black). Red
square, glucagon secretion and G at 1 mM
glucose. ***p < 0.001 versus no diazoxide.
(D) Effects of glucose and diazoxide on glucagon
secretion in the absence and presence of 2–6 mM
of amino acidmixtures (see Table S1). Glucose and
diazoxide were also added to the medium, as in-
dicated. n = 8–9 experiments. **p < 0.01 for effects
of 1 mM glucose versus 6 mM glucose (at 0, 2, or
6mMAAM); zp< 0.05 for effect of diazoxide versus
no diazoxide at 6 mM glucose in the presence of
2 mM AAM; {p < 0.05 for effect of diazoxide at
1 mM glucose in the presence of 6 mM AAM.
Error bars indicate SEM. See also Figure S2 and
Table S1.
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KATP Channels and Glucagon SecretionThe reported >5-fold greater ATP sensitivity of KATP-channel ac-
tivity in a cells than in b cells (Leung et al., 2005) might contribute
to the strong tonic inhibition of KATP-channels in a cells.
Relationship between KATP Channel Activity and
Glucagon Secretion
Diazoxide activated KATP-channels inhibited by glucose, with
half-maximal stimulation occurring at 29± 6 mM (n= 5; Figure 3B).
Glucagon secretion was measured in the presence of 6 mM
glucose (to maximally inhibit secretion) and increasing concen-
trations of diazoxide. This enables the relationship between
KATP conductance (G, determined as above) and glucagon
secretion to be determined over a wider range of conductance
than can be obtained by varying glucose concentration (Fig-
ure 3C). The G-secretion relationship was bell shaped, being
maximal at 280 pS (3 mM diazoxide), where both G and secre-
tion were similar to that at 1 mM glucose. Importantly, both small
(100 pS) increases and decreases in G inhibited glucagon
secretion. The ability of diazoxide to reverse the effects of
glucose cannot be explained by relief from paracrine suppres-
sion of glucagon secretion by insulin or somatostatin, as
glucose-induced release of these hormones is unaffected by
diazoxide concentrations as high as 30 mM and 200 mM, respec-
tively (MacDonald et al., 2007; Zhang et al., 2007).874 Cell Metabolism 18, 871–882, December 3, 2013 ª2013 The AutThe data of Figure 3C confirm our earlier finding (MacDonald
et al., 2007), that low concentrations of diazoxide antagonize the
inhibitory effect of glucose on glucagon secretion. We also tested
the effects of glucose and diazoxide in the presence of two
different amino acid mixtures, AAMa (2 mM) and AAMb (6 mM),
designed to simulate theconditionsoccurringduring fasting (Rud-
man et al., 1989) and following a protein-rich meal, respectively
(Figure3D). AAMadid not detectably enhance glucagon secretion
beyond that evokedby1mMglucose. Increasingglucose to6mM
in the presence of AAMa inhibited glucagon secretion as strongly
as it did under control conditions, an effect that was prevented by
diazoxide. In fact, diazoxide stimulated glucagon secretion in the
presence of 6 mM glucose. AAMb stimulated glucagon secretion
4-fold at 1 mM glucose and elevation of glucose to 6 mM
reduced glucagon secretion by >60%. Again, no inhibitory effect
of glucosewasobserved in thepresenceof 3mMdiazoxide. These
observations argue that KATP-channel closure plays a key role in
the modulation of glucagon secretion by glucose in both the
absence and presence of amino acids.
Membrane Potential-Dependent Reduction of Action
Potential Height
Figures 2 and 3 suggest KATP-channel closure leads to mem-





Figure 4. Impact of Membrane Potential on
Action Potential Amplitude
(A) Electrical activity in mouse a cells hyper-
polarized to 80 mV by injection of 5 pA and
stimulated by 5 s current pulses to different
membrane potentials applied at a frequency of
0.2 Hz.
(B) Individual spikes from (A), as indicated by
asterisks, shown on an expanded timescale.
(C) Relationship between interspike membrane
potential and action potential peak voltage (Vp).
The amplitude of each action potential and the
associated interspike voltage were measured.
For display, data were binned according to the
most negative interspike potential (bin width,
5 mV) and averaged (n = 7–12 action potentials
for each data point). The line is a Boltzmann fit
to the mean data with a midpoint of 52 mV.
The red arrow indicates the decrease in peak
voltage predicted from the 9 mV glucose-induced
depolarization.
(D) Voltage-dependent inactivation of Na+-current
in identified a cells in intact islets. Peak currents
during a 1 ms test pulses to 0 mV are displayed
against the membrane potential during the
preceding 200 ms conditioning pulses (fre-
quency, 1 Hz). Current responses are presented as
hN (= I/Imax). The response following a conditioning
pulse to 100 mV was taken as unity (n = 6). The
midpoint of inactivation was 47 mV. Arrow in-
dicates the decrease in hN predicted from the
glucose-induced depolarization. (Inset) Na+-cur-
rents during depolarizations to 0 mV following
conditioning pulses to 100 mV, 55 mV, and
45 mV. See also Table S1.
(E) Examples of action potentials recorded from an a cell in an intact islet exposed to 1 mM glucose under control conditions, after addition of TTX (0.1 mg/ml) and
following washout of the blocker (ten individual spikes averaged for each experimental condition).
(F) Effects of TTX on glucagon secretion measured from isolated NMRImouse islets at 1 mMglucose in the absence and presence of TTX (as indicated). *p < 0.05
versus 1 mM glucose without TTX.
(G) Absolute (left) and relative (right) glucagon secretion from mouse islets at 1 mM glucose and different [K+]o (n = 6). Relative release is normalized to that at
3.6 mM [K+]o). The red arrow indicates the equivalent decrease (47% ± 4%) in glucagon secretion produced by increasing glucose from 1 mM to 6 mM in control
experiments (at 3.6mM [K]o; seven different experimental series performed over several years). (Inset) Stimulation of glucagon secretion by 70mM [K
+]o. *p < 0.01
and ***p < 0.001 versus 3.6 mM [K+]o.
Error bars indicate SEM.
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KATP Channels and Glucagon SecretionWe investigated the relationship between interspike membrane
potential and the voltage at the peak of the action potential
(Figures 4A and 4B). Peak voltage decreased with interspike
depolarization, from +18 ± 6 mV at negative membrane poten-
tials (below 60 mV) to 14 ± 2 mV at depolarized potentials
(above 40 mV), being half-maximal at 52 ± 3 mV with a slope
factor of 4 ± 1 mV (n = 4 cells from four different islets and three
different mice; Figure 4C). Using these values, we estimate that
the 9 mV depolarization produced by increasing glucose from
1mM to 6 mMwill reduce action potential peak voltage from +6-
mV to 9 mV, in reasonable agreement with values observed
experimentally (Figure 2A). Thus, the glucose-induced changes
in membrane potential are sufficient to account for the reduction
of action potential height.
Action potential firing in a cells depends on the opening of
voltage-gated Na+-channels (Go¨pel et al., 2000b). We reasoned
that glucose-induced membrane depolarization might reduce
action potential height by voltage-dependent inactivation of
Na+-channels. In agreement with this idea, the Na+-channelCell Mblocker TTX (0.1 mg/ml) reduced action potential peak voltage
in a cells exposed to 1 mM glucose by 14 ± 4 mV (n = 5; p <
0.01; Figure 4E), reduced dV/dtd from 37 ± 12 V/s to 11 ± 2 V/s
(p < 0.05 versus no TTX), and reduced dV/dtr from 22 ± 4 V/s
to13 ± 3 V/s (p < 0.05 versus no TTX). It also inhibited glucagon
secretion at 1 mM glucose by 40% (Figure 4F). The peak Na+-
current amplitude in identified a cells decreased steeply at po-
tentials positive to 60 mV (Figure 4F): the relationship between
membrane potential and peakNa+-current predicts that the 9mV
depolarization produced by glucose will reduce the fraction of
active Na+-channels (hN) from 0.7 to 0.3 (red arrow). These
data argue that glucose-induced membrane depolarization me-
diates its effect on action potential height via (partial) voltage-
dependent inactivation of voltage-gated Na+-channels.
We next explored the effect of membrane potential on
glucagon secretion, by varying the extracellular K+ concentration
([K+]o) (Figure 4G). In the presence of 1 mM glucose, elevation of
[K]+o from 1.5 mM to 12 mM progressively decreased glucagon





Figure 5. Ca2+ Channel Activation and
Exocytosis in a Cells
(A) Voltage dependence of a cell exocytosis (n = 5)
was measured as changes in membrane capaci-
tance (DCm) in response to 500 ms voltage pulses
(holding potential 70 mV) using the standard
whole-cell configuration. DCm was normalized to
the largest response in each cell (DCmax). The red
arrow indicates the 75% suppression of exocy-
tosis predicted to result from a 9 mV reduction of
the action potential.
(B) Glucagon secretion from islets exposed to
glucose and u-agatoxin, as indicated (n = 6). **p <
0.01 versus 1 mM glucose under control condi-
tions; yyyp < 0.001 versus 1 mM glucose under
control conditions.
(C) DCm recorded during 500 ms depolarizations
to 0 mV in a cells with/without 200 nM u-agatoxin
(n = 4). *p < 0.05 versus no u-agatoxin.
(D) u-agatoxin-sensitive Ca2+-currents (lower)
evoked by voltage-clamp commands based on
the averages of 20 action potentials recorded in
the presence of 1 and 6 mM glucose (top).
(E and F) DCm recorded during 50 and 300 ms depolarizations to 0 mV with intracellular EGTA included in the pipette medium at 50 mM (E) or 1 mM (F).
(G) DCm recorded in the perforated patch whole-cell configuration at 1 and 6 mM glucose in response to 500 ms voltage pulses from 70 mV to 0 mV (n = 10).
Error bars indicate SEM. See also Figure S3 and Table S1.
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KATP Channels and Glucagon Secretion[K+]o (70mM) stimulated glucagon secretion >4-fold (inset). From
the relationship between [K+]o and glucagon secretion we
estimate that elevating [K+]o from 3.6 mM to 9 mM is required
to produce the same inhibition of glucagon secretion as that
resulting from an increase in glucose from 1mM to 6mM (arrow).
This increase in [K+]o corresponds to an estimated 13 mV
depolarization (estimated from the relationship between [K+]o
and a cell membrane potential reported previously; De Marinis
et al., 2010), which is in reasonable agreement with the
9 mV glucose-induced depolarization observed experimentally
(Figure 2A).
Glucose Inhibits Glucagon Secretion by Reducing
P/Q-Type Ca2+ Channel Activation
Figure 5A summarizes the voltage dependence of exocytosis in
identified a cells in intact islets. The relationship predicts that the
9 mV reduction in spike height produced by glucose reduces
exocytosis by 75%.
Glucagon exocytosis is dependent on Ca2+ entry via voltage-
gated Ca2+-channels (see Figure S3). The P/Q type Ca2+-chan-
nel blocker u-agatoxin mimicked the inhibitory effect of 6 mM
glucose (Figure 5B) and inhibited depolarization-evoked exocy-
tosis (Figure 5C). The reduction in action potential height pro-
duced by 6 mM glucose resulted in 66% ± 10% (n = 5; p <
0.01) inhibition of the peak P/Q type Ca2+-current evoked by
simulated action potentials (Figure 5D). During brief depolariza-
tions (%50 ms), exocytosis proceeded only during the depolari-
zation (Figure 5E), and not subsequent to it (cf. Zhang et al.,
2007). This suggests exocytosis in a cells is controlled by rapid,
local [Ca2+]i increases, close to the Ca
2+-channel, and thus
echoes Ca2+-channel activity. Accordingly, exocytosis elicited
by short depolarizations was hardly affected by inclusion of the
Ca2+-chelator EGTA (1 mM) in the intracellular medium (Fig-
ure 5F). On average, 50 ms depolarizations evoked capacitance
increases of 14 ± 6 fF (n = 8) and 11 ± 2 fF (n = 5) in the presence876 Cell Metabolism 18, 871–882, December 3, 2013 ª2013 The Autof 50 mM and 1 mM intracellular EGTA, respectively. However,
exocytosis evoked by 300 ms depolarizations was reduced
from 80 ± 20 fF to 30 ± 11 fF (p < 0.05), suggesting that Ca2+ diffu-
sion during longer depolarizations may trigger exocytosis of
granules not situated in the immediate vicinity of the Ca2+-
channels.
Glucose (6 mM) did not inhibit a cell exocytosis evoked by
membrane depolarization to 0mV in perforated patch recordings
(Figure 5G). This indicates that the glucose-induced suppression
of glucagon secretion is secondary to changes in membrane
potential rather than a direct effect of the sugar on exocytosis.
Effects of KATP Channel Mutations Associated with
Reduced ATP Sensitivity on Glucagon Secretion
An increase in KATP-channel activity either stimulates or inhibits
glucagon secretion, depending on the magnitude of the increase
in the KATP current (Figure 3C). The question then arises as
to whether gain-of-function mutations found in patients with
neonatal diabetes (Gloyn et al., 2004) affect glucagon secretion.
We addressed this by generating mice expressing KATP-chan-
nels with reduced ATP-sensitivity in a cells (a-V59Mmice). These
had normal body weight (data not shown) and fasting blood
glucose levels but exhibited mild glucose intolerance (Figures
S4A and S4B) and increased insulin sensitivity (Figure S4C).
In 1 mM glucose, the membrane conductance (G) was >13-
fold larger in metabolically intact a cells in islets isolated
from a-V59M mice than in control islets (1.5 nS/pF versus
0.11 nS/pF; p < 0.03; a cells identified by expression of tdRFP).
Whereas 6 mM glucose reduced G in control a cells by 17% ±
5%, no reduction was detected in a-V59M a cells (Figure 6A).
Tolbutamide reduced G by >50% in mutant a cells (Figure 6B),
but it still remained >4-fold higher than in control a cells.
We next measured a cell electrical activity in intact control and
a-V59M islets. In contrast to control cells (which resemble wild-





Figure 6. Effects of the Kir6.2-V59M Muta-
tion on Glucagon Secretion
(A and B) Whole-cell resting conductance (Gr)
measured with the perforated patch method in a
cells within control (A; n = 6–7) and a-V59M islets
(B; n = 6) at the indicated concentrations (mM) of
glucose and tolbutamide. *p < 0.05 versus 1 mM
glucose. yp < 0.05 versus 1 mM glucose in control
a cells. Inset in (A) shows conductance changes on
an expanded vertical axis.
(C) Electrical activity in a cells in a-V59M islets at
the indicated glucose (black bar) and tolbutamide
(red bar) concentrations. Examples showing a
cells (i) refractory to glucose but responding to
tolbutamide and (ii) stimulated by glucose and
where tolbutamide reduced spike height.
(D) Glucagon secretion from control (left and black;
n = 15–21 from 8mice) and a-V59M islets (right and
red; n = 26 from 12 mice) at the indicated glucose
and tolbutamide concentrations (in mM). ***p <
0.001 versus 1 mM glucose (control islets), yyp <
0.01 versus 1 mM glucose (a-V59M islets), and
zp < 0.05 versus 6 mM glucose in control islets.
(E) Effects of adrenaline (adr.; 5 mM) on glucagon
secretion at 1 mM glucose in wild-type type (left;
n = 6) and a-V59M islets (right; n = 9). *p < 0.05 and
**p < 0.01 versus 1 mM glucose (for comparisons
within strain).
(F) As in (E), but testing the effects of membrane
depolarization produced by increasing extracel-
lular K+ to 70 mM. *p < 0.05 and **p < 0.01 versus
3.6 mM [K+]o (for comparisons within strain) and
zp < 0.05 versus 70 mM [K+]o in control islets.
Error bars indicate SEM. See also Figure S4 and
Table S1.
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polarized (79 ± 3 mV). When glucose was elevated to 15 mM,
two cells depolarized and generated electrical activity, five
were refractory to glucose but responded to tolbutamide, and
one did not respond to either agent (Figure 6C).
Glucagon content was similar in wild-type and a-V59M islets,
averaging 1,589 ± 213 pg/islet and 2,093 ± 207 pg/islet, respec-
tively. Unexpectedly, although 80% of a-V59M a cells were elec-
trically silent at 1 mM glucose, glucagon secretion from a-V59M
islets was not less than from control islets (Figure 6D). Notably,
the inhibitory effect of glucose was halved in a-V59M islets
(18% versus 35%) whereas tolbutamide was as inhibitory as
in control islets (30%). In control islets, adrenaline (5 mM) stimu-
lated glucagon secretion 4-fold, but this effect was strongly
reduced ina-V59M islets (Figure6E); theadrenaline-inducedstim-
ulation averaged 7 ± 1 and 24 ± 4 pg/islet/hr (p < 0.05), respec-
tively. By contrast, glucagon secretion evoked by 70 mM K+
was 2.9-fold larger in a-V59M than in wild-type islets (Figure 6F).
A Small Increase in KATP Channel Activity Mimics the
Effects of Type 2 Diabetes on Glucagon Secretion
Type 2 diabetes (T2D) is associated with loss of glucose-induced
suppression of glucagon secretion—indeed, stimulation may
occur instead (Dunning et al., 2005). We evaluated if this distur-
bance is intrinsic to the islet, using islets isolated from T2D and
nondiabetic (ND) organ donors (Figure 7A). In ND islets, glucose
(6 mM) inhibited glucagon secretion by 50%. No inhibition byCell Mglucose was seen in T2D islets. In fact, glucose stimulated
glucagon secretion in 5 of the 10 T2D preparations tested but
in only 4 of 46 ND preparations (p < 0.001 by c2). Glucagon con-
tent was 2.5-fold higher in T2D islets than in ND islets (2,457 ±
461 pg/islet versus 985 ± 105 pg/islet; p < 0.01). The relative
effect of glucose on glucagon secretion in ND and T2D islets
is summarized in Figure 7F. On average, glucose inhibited
glucagon secretion by 43%± 6% in ND islets but tended to stim-
ulate glucagon secretion by 15% ± 24% in T2D islets. In the five
preparations where glucose had the least inhibitory effect,
glucose enhanced glucagon secretion by 74% ± 28%. In the re-
maining five preparations, glucose inhibited glucagon secretion
by 44% ± 9% (data not shown).
The inverted response to glucose seen in 50% of T2D islet
preparations could be induced in ND islets by 2 mM diazoxide
(Figure 7B), which increases KATP-channel activity by 80 pS
(Figure 3B). In the presence of diazoxide, 6 mM glucose stimu-
lated rather than inhibited glucagon secretion. Similar results
were observed in mouse islets (data not shown).
A common variant (E23K; rs5219) in KCNJ11 (which encodes
the Kir6.2 subunit of the KATP-channel) is associated with en-
hancedT2D risk (Gloynetal., 2003), increasedKATP-channel activ-
ity (Schwanstecher et al., 2002), and impaired glucose-induced
suppression of glucagon secretion in vivo (Tschritter et al.,
2002). However, we found no difference in the inhibitory effect
of glucoseonglucagonsecretion in vitro inNDhuman isletshomo-
zygous for the high-risk TT or low-risk CC variants (Figure 7C).etabolism 18, 871–882, December 3, 2013 ª2013 The Authors 877
A B C
D E F
Figure 7. Glucagon Secretion and Type 2 Diabetes
(A) Glucagon secretion at 1 and 6 mM glucose in islets from human organ donors without (ND) and with known T2D normalized to glucagon content. White bars
show glucagon secretion in the five islet preparations where glucose stimulated glucagon release. ***p < 0.001 versus 6 mM glucose; yp < 0.02 versus 1 mM
glucose in five T2D preparations with no glucose-induced inhibition of glucagon secretion.
(B) Glucagon secretion in the absence (black) and presence (red) of 2 mMdiazoxide in ND human islets (n = 7 experiments, using islets from two donors). *p < 0.05
versus 1 mM glucose. yp < 0.05 versus 1 mM glucose in the presence of diazoxide.
(C) Glucagon secretion from islets of nondiabetic human donors homozygous for the high-risk (TT; n = 6) and low-risk (CC; n = 8) Kir6.2 (KCNJ11) alleles. *p < 0.05
and **p < 0.01 versus 1 mM glucose.
(D) Glucagon secretion from mouse islets at 1 mM and 6 mM glucose in the absence (black) and presence (red) of 0.5 mM oligomycin (n = 8–16). Tolbutamide
10 mM was added as indicated. ***p < 0.001 versus 1 mM glucose; yyyp < 0.001 versus 1 mM glucose plus oligomycin; zzp < 0.01 versus 1 mM glucose without
oligomycin; xp < 0.05 versus 1 mM glucose with oligomycin (no tolbutamide); {p < 0.05 versus 1 mM glucose plus oligomycin (with tolbutamide).
(E) Effects of glucose (1 or 6mM) on glucagon secretion normalized to glucagon content in islets from T2D donors in the absence (left) and presence (right; n = 4) of
tolbutamide (10 mM). *p < 0.05 versus 1 mM glucose.
(F) Relative effect (%) of elevating glucose from 1 to 6 mM on glucagon secretion in ND (black) and T2D islets (color coded as in A) and in four T2D preparations in
the presence of tolbutamide (far right). Significance between 1 mM and 6 mM glucose is indicated. ***p < 0.001, **p < 0.02, *p < 0.05.
Error bars indicate SEM. See also Figures S5 and S6 and Table S1.
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mitochondrial ATP synthase, converted the inhibitory effect of
glucose on glucagon secretion into stimulation (Figure 7D). The
ability of glucose to stimulate (rather than inhibit) glucagon
secretion in islets treated with oligomycin suggests a regulatory
role of nonmitochondrial metabolism in a cells. Interestingly,
tolbutamide (10 mM) restored normal glucose regulation of glu-
cagon release from oligomycin-treated islets (Figure 7D) without
correcting insulin secretion (data not shown). Collectively, these
data suggest that in 50% of T2D patients, possibly because of
a metabolic disturbance, KATP-channel activity is slightly in-
creased with resultant loss of glucose-induced suppression of
glucagon secretion. If this hypothesis is correct, then it should
be possible to reverse the glucagon secretion defect in T2D
with tolbutamide. Indeed, as shown in Figures 7E and 7F, tolbu-
tamide (10 mM) partially restored glucose inhibition of glucagon
secretion in islets from four T2D organ donors.
DISCUSSION
Our data show that pancreatic a cells respond to glucose with
closure of KATP-channels and suggest that glucose modulates878 Cell Metabolism 18, 871–882, December 3, 2013 ª2013 The AutKATP-channel activity and glucagon secretion via increased cyto-
plasmic ATP/ADP (Figure 1B). Although we favor the idea that
a cells possess an intrinsic glucose sensing mechanism, we
cannot rule out the involvement of the b cell metabolite GHB
(g-hydroxybutyrate), recently proposed to mediate the inhibitory
effect on glucagon secretion (Li et al., 2013). The mechanism by
which activation of the GHB receptor would inhibit glucagon
secretion has not been established, but our data suggest it
may culminate in KATP-channel closure.
Role of KATP Channels in Regulating a Cell Excitability
In most cells, K+-channel activity dampens cellular excitability by
producing membrane hyperpolarization. Conversely, closure of
K+-channels promotes electrical excitability. The b cell conforms
to this principle: KATP channel closure causes membrane depo-
larization, electrical activity, and insulin secretion. Strikingly, in a
cells, KATP channel closure also causes depolarization but para-
doxically inhibits glucagon secretion. Figure S5 illustrates how
our data suggest this difference between a and b cells arises.
Crucially, in a cells, net KATP-channel activity at 1 mM glucose
(50 pS; Figure 3A) is only 0.5%–1.5% of the 3–9 nS measured
under comparable conditions in b cells (Go¨pel et al., 2000a;hors
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KATP Channels and Glucagon SecretionZhang et al., 2008). As a result, a cells are electrically active at
low glucose, stimulating glucagon secretion. Glucose elevation
inhibits remaining KATP channel activity, producing a further de-
polarization that partially inactivates voltage-dependent Na+-
channels and decreases spike height. This reduces P/Q-type
Ca2+-current activation and glucagon exocytosis. Although
glucose also increases action potential frequency (+200%; Fig-
ure 2), this is insufficient to compensate for the reduced exocy-
tosis (75%; Figure 5A). The combination of these two effects
can be estimated to result in50% inhibition of glucagon secre-
tion, in good agreement with that observed experimentally
(Figures 1A, 1C, and 1D).
The much larger KATP conductance at 1 mM glucose keeps
b cells hyperpolarized and electrically silent at low glucose, so
that no insulin is secreted. Glucose closes KATP-channels and
thereby triggers depolarization, electrical activity, and insulin
secretion from a very low basal level. As in a cells, there is also
a time-dependent reduction in spike height, but insulin secretion
will remain much greater than in 1 mM glucose even after the
reduction of spike height has occurred.
Our data suggest that tolbutamide and glucose affect electri-
cal activity and glucagon secretion in freshly isolated islets by
identical mechanisms. Very recently, glucose was postulated
to inhibit glucagon secretion by a KATP-channel-independent
(as yet unidentified) mechanism (Cheng-Xue et al., 2013), but
the observation that the glucose-sensitive component of
glucagon secretion was reduced by >85% in islets lacking
KATP-channels argues that this mechanism is of relatively minor
significance.
Resting Activity of KATP Channels Determines Islet
Hormone Release
The model outlined above postulates that the KATP-channel
plays a dual role in the regulation of insulin and glucagon secre-
tion. Depending on the initial activity, channel closure may either
stimulate (b cells) or inhibit (a cells) secretion. Thus, increasing
basal KATP activity in a cells may result in a b cell phenotype—
i.e., no electrical activity or glucagon secretion at 1 mM glucose,
and stimulation of both by glucose. This is precisely what is seen
in the presence of low concentrations of diazoxide (Figure 7B).
Similarly, we observed that glucose stimulates electrical activity
in some a-V59M a cells (Figure 6C). Figure S6 illustrates the rela-
tionship between KATP-channel activity and glucagon secretion.
Cells with little or no expression of mutant channels behave like
control cells (Figure S6A). Cells expressing high levels of mutant
channels (or exposed to high concentrations of diazoxide) will be
permanently hyperpolarized and show no glucagon secretion at
either 1 or 6 mM glucose (Figure S6B). Cells lying between these
extremes will show a spectrum of responses: in some, 6 mM
glucose will stimulate glucagon secretion (Figure S6C); in others,
glucagon release will be high and unaffected by glucose (Fig-
ure S6D). It is of interest that the whole-cell KATP conductance
is 3-fold larger in isolated rat a cells (Olsen et al., 2005) than
that we observe in intact mouse islets. This may account for
the paradoxical glucose-induced stimulation of glucagon secre-
tion observed in single a cells.
Recently it was reported that the impaired counterregulation of
glucagon secretion in diabetic rats could be restored by a
somatostatin receptor antagonist (Yue et al., 2012), suggestingCell Mthat somatostatin signaling is enhanced in diabetic islets. The
effects of somatostatin on a cells include activation of K+-chan-
nels (GIRK) (Kailey et al., 2013). The resulting increase in GIRK-
channel activity could be envisaged to have the same effect on
glucagon secretion as a low concentration of diazoxide or
weak expression of mutant KATP-channels.
Unexpectedly, glucagon secretion is close to normal in
a-V59M islets, although a cell electrical activity is strongly
affected (Figures 6C and 6D). This is consistent with the mild
metabolic phenotype of a-V59M mice (Figures S4A and S4B)
and suggests that glucagon secretion is upregulated in the
20% of a cells that remain active. However, the response to
adrenaline was reduced by >70% (Figure 6E) in a-V59M islets,
a finding that may explain the impaired insulin tolerance of
a-V59M mice (Figure S4C). The stimulatory effect of adrenaline
on glucagon secretion involves electrical activity and requires
influx of extracellular Ca2+ (De Marinis et al., 2010). Thus, it
seems likely that in a cells expressing mutant KATP-channels,
which are electrically silent, adrenalinewill bewithout stimulatory
effect. Collectively, these findings argue that the subset of a cells
in a-V59M islets that remain electrically active operate close to
their maximum secretory capacity already at 1 mM glucose,
accounting for the smallness of the adrenaline effect. This is
reminiscent of reports of near-normal glucagon secretion in
islets after almost total (98%) ablation of a cells by diphtheria
toxin (Thorel et al., 2011). If this hypothesis is correct, then
glucagon secretion evoked by experimental paradigms that
bypass action potential firing should be enhanced in a-V59M
islets. Indeed, high-[K+]o depolarization (which stimulates secre-
tion in both electrically active and electrically silent a cells)
produces a much larger stimulation of glucagon secretion in
a-V59M than in control islets (Figure 6F).
It may seem surprising that glucose remains capable of inhib-
iting glucagon secretion in a-V59M islets despite no detectable
glucose-induced reduction of KATP-channel activity. However,
for the reasons we outlined above, glucagon secretion will prin-
cipally reflect the activity of the small subset of cells in which
KATP-channel activity is normal. By contrast, measurements of
KATP-channel activity will be dominated by a cells expressing
high levels of mutant KATP channels, which respond poorly to
glucose. Importantly, in some a cells, expression of mutant
KATP-channels is low and total KATP-channel activity onlymargin-
ally increased, just sufficient to suppress electrical activity at
1 mM glucose. However, when glucose is elevated and KATP-
channel activity is reduced, these a cells undergo depolarization
and start firing action potential with resultant stimulation of
glucagon secretion. This opposes the glucose-induced inhibition
in other cells and explains the reduced glucose-induced inhibi-
tion of glucagon secretion in a-V59M mutant islets.
In general, the subtle impact of targeting the Kir6.2-V59M
mutation to the a cell on glucagon secretion suggests that
enhanced a cell KATP-channel activity is unlikely to affect
glucagon secretion in patients with neonatal diabetes due to
gain-of-function KATP-channel mutations.
Implications for Type 2 Diabetes
In T2D, glucagon secretion in vivo is often stimulated rather than
inhibited during hyperglycemia (Dunning et al., 2005). We
observed a similar abnormality in 50% of islet preparationsetabolism 18, 871–882, December 3, 2013 ª2013 The Authors 879
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exhibited normal glucose regulation. Thus, T2D islets are hetero-
geneous with respect to the dysregulation of glucagon secretion,
in agreement with a recent report (Li et al., 2013). Intriguingly, the
inverted response to glucose seen in some T2D islet prepara-
tions can be mimicked in ND islets by a small increase (0.5%)
in KATP-channel activity produced by diazoxide (Figure 7B).
Similarly, metabolic inhibition, which activates KATP-channels,
affects glucagon secretion in the same way as T2D (Figure 7D).
This suggests that T2D may be associated with increased
KATP-channel activity, possibly as a consequence of impaired
islet metabolism (Doliba et al., 2012). It is notable that glucagon
secretion in the presence of diazoxide or oligomycin shows not
only an inverted glucose response but also reduced secretion
at 1 mM glucose. This is reminiscent of the impaired counterre-
gulation that is a feature of longstanding T2D, raising the
interesting possibility that T2D may involve a progressive and
time-dependent increase in K+-channel activity and deteriora-
tion of the metabolic regulation of glucagon secretion. It is there-
fore of interest that a low concentration of the KATP-channel
blocker tolbutamide restores normal glucose regulation of
glucagon secretion in metabolically compromised islets (Fig-
ure 7D) and improves it in islets from donors with T2D (Figures
7E and 7F). Possibly, low-dose sulfonylurea (much less than
required to stimulate insulin secretion) may be a useful addition
to insulin therapy. Finally, our data suggest that a single cellular
disturbance (impaired glucosemetabolism and ATP production),
via increased KATP-channel activity, may explain the trio of
hormone secretion defects associated with T2D: impaired
glucose-induced insulin secretion, inverted glucose regulation
of glucagon secretion, and defective counterregulation.
EXPERIMENTAL PROCEDURES
All experiments were conducted in accordance with the UK Animals Scientific
Procedures Act (1986) and University of Oxford ethical guidelines.
Media
Media used are specified in Table S1.
Animals and Generation of a-V59M Mice
Most experiments were performed on islets isolated from NMRI mice
obtained from a commercial supplier. Mice expressing Kir6.2-V59M in a
cells (a-V59M mice) were generated using a Cre-lox approach (Clark et al.,
2010).
Human Islets
Human islets (obtained with ethical approval and clinical consent) were iso-
lated from pancreases of 46 nondiabetic donors and 10 donors with T2D.
Genotyping of Human Islet DNA
The rs5219 variant was genotyped using an allelic discrimination assay-by-
design method on an ABI 7900 analyzer (Applied Biosystems).
Hormone Release Measurements
Measurements of insulin and glucagon secretion were performed using the
in situ pancreas perfusion or static incubations of isolated islets.
Electrophysiology
All electrophysiological measurements were performed at +34C on a cells
within intact islets (from NMRI or a-V59M and control mice).
For themembrane potential andwhole-cell KATP-current recordings (Figures
2A–2C), the perforated patch technique was employed as reported previously880 Cell Metabolism 18, 871–882, December 3, 2013 ª2013 The Aut(De Marinis et al., 2010). The pipette solution consisted of IC1, and the bath
contained EC2.
Exocytosis was measured as increases in membrane capacitance in a cells
in intact islets as described previously (Go¨pel et al., 2004) using pipette
medium IC2 and extracellular medium EC3. The impact of glucose on
exocytosis was tested using the perforated patch technique using pipette
medium IC3.
Voltage-dependent inactivation of the Na+-current was evaluated using the
standard whole-cell technique and a two-pulse protocol using intra- and extra-
cellular media IC4 and EC4, respectively.
ATP Imaging
The ATP/ADP sensor Perceval (Berg et al., 2009) was used as previously
described (Tarasov et al., 2012).
Identification of a Cells
The identity of the a cells was established either by (1) immunocytochemistry
following injection of the cell with biocytin (0.5 mg/ml) via the recording elec-
trode (Figures S2C and S2D) or (2), in the case of a-V59M and control a cells,
by tdRFP fluorescence. In perforated patchmeasurements of electrical activity
and KATP-channel activity in NMRI islets (Figures 2–4), it was not always
possible to identify the cell by immunocytochemistry because the cell
detached when retracting the recording electrode. In these cases, a cells
were identified by their spontaneous action potential firing at 1 mM glucose
(Go¨pel et al., 2000a).
Statistical Analysis
Details on the analysis of the electrophysiological data are given in the Supple-
mental Information. Data are presented as man values ± SEM of the indicated
number of experiments (n). Error bars in figures represent SEM. Statistical sig-
nificances were, unless otherwise indicated, evaluated using Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article at http://dx.doi.
org/10.1016/j.cmet.2013.10.014.
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